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BACKGROUND: Therapeutic options for patients with advanced hepatocellular carcinoma (HCC) are limited. There is emerging
evidence that the growth of cancer cells may be altered by very low levels of electromagnetic fields modulated at specific frequencies.
METHODS: A single-group, open-label, phase I/II study was performed to assess the safety and effectiveness of the intrabuccal
administration of very low levels of electromagnetic fields amplitude modulated at HCC-specific frequencies in 41 patients with
advanced HCC and limited therapeutic options. Three-daily 60-min outpatient treatments were administered until disease
progression or death. Imaging studies were performed every 8 weeks. The primary efficacy end point was progression-free survival
X6 months. Secondary efficacy end points were progression-free survival and overall survival.
RESULTS: Treatment was well tolerated and there were no NCI grade 2, 3 or 4 toxicities. In all, 14 patients (34.1%) had stable disease
for more than 6 months. Median progression-free survival was 4.4 months (95% CI 2.1–5.3) and median overall survival was 6.7
months (95% CI 3.0–10.2). There were three partial and one near complete responses.
CONCLUSION: Treatment with intrabuccally administered amplitude-modulated electromagnetic fields is safe, well tolerated, and shows
evidence of antitumour effects in patients with advanced HCC.
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Treatment of inoperable or metastatic solid tumours is a major
challenge in oncology, which is limited by the small number of
therapeutic agents that are both well tolerated and capable of long-
term control of tumour growth. Hepatocellular carcinoma (HCC)
is the second most common cause of cancer death in men and the
sixth in women worldwide (Jemal et al, 2011). Hepatocellular
carcinoma is the most common tumour in certain parts of the
world, particularly in East Asia, Africa, and certain countries of
South America. This tumour is less frequent in Europe and in the
United States, but has become the fastest rising cancer in the
United States (Jemal et al, 2011). In the United States alone, it is
estimated that 24120 new cases were diagnosed and there were
17430 deaths from HCC in 2010 (Jemal et al, 2010), a 27% increase
in the number of new cases since 2004 (Jemal et al, 2004). The
prognosis of patients suffering from advanced HCC is poor with an
average survival of fewer than 6 months (Kassianides and Kew,
1987; Jemal et al, 2011).
Therapies for HCC are limited. Resections of the primary
tumour or liver transplantation are the preferred therapeutic
approaches in patients who are surgical candidates (Bruix and
Sherman, 2005). Although these interventions result in long-term
survival for some patients, only a minority benefit from them
because of limitations due to tumour size, patient’s overall
condition, and presence of hepatic cirrhosis (Cance et al, 2000).
Only a small number of randomised trials show a survival benefit
in the treatment of HCC. Chemoembolisation has been shown to
confer a survival benefit in selected patients with unresectable
HCC (Llovet et al, 2002). Data from two phase III randomised
placebo-controlled studies demonstrate improved survival in
patients with advanced HCC receiving the multikinase inhibitor
sorafenib (Llovet et al, 2008b; Cheng et al, 2009). Additional
therapies for this disease are sorely needed, especially for the large
number of patients with advanced disease who cannot tolerate
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schemotherapy or intrahepatic interventions because of impaired
liver function (Thomas and Zhu, 2005).
The intrabuccal administration of low and safe levels of
electromagnetic fields, which are amplitude-modulated at dis-
ease-specific frequencies (RF AM EMF) (Figure 1), was originally
developed for the treatment of insomnia (Pasche et al, 1990). The
highest levels of EMFs encountered during treatment are found at
the interface between the tongue and the mouth probe and are
compliant with international safety limits (ICNIRP, 1998; Pasche
and Barbault, 2003). Tumour-specific modulation frequencies have
been identified for several common forms of cancer and one report
suggests that this novel therapeutic approach is well tolerated and
may be effective in patients with a diagnosis of cancer (Barbault
et al, 2009). However, the safety and potential efficacy of this
treatment approach in the treatment of advanced HCC are
unknown. We designed this single-group, open-label, phase I/II
study to assess the feasibility of this treatment in patients with
advanced HCC and limited therapeutic options.
PATIENTS AND METHODS
Patients
The study was aimed at offering treatment to patients with Child–
Pugh A or B advanced HCC and limited therapeutic options.
Patients were classified as having advanced disease if they were not
eligible for surgical resection or had disease progression after
surgical or locoregional therapies or had disease progression after
chemotherapy or sorafenib therapy. Patients with measurable,
inoperable HCC were eligible for enrolment. Previous local or
systemic treatments were allowed as long as they were discon-
tinued at least 4 weeks before enrolment. Inclusion criteria
included Eastern Cooperative Oncology Group performance status
of 0, 1, or 2 and biopsy-confirmed HCC. Also allowed were patients
with no pathological confirmation of HCC with a level of
a-fetoprotein higher than 400ngml
 1 and characteristic imaging
findings as assessed by multislice computer tomography (CT) scan
or intravenous contrast ultrasound (US). As per the University of
Sa ˜o Paulo Department of Transplantation and Liver Surgery
guidelines, liver biopsies are avoided in patients eligible for
transplant or with severely impaired liver function. Exclusion
criteria included confirmed or suspected brain metastasis,
Child–Pugh C, previous liver transplant, and pregnancy.
Study design
This was an investigator-initiated, single centre, uncontrolled
phase I/II trial in patients with advanced HCC. The trial was
approved by the local human investigation committee and
conducted in accordance with the Declaration of Helsinki. Written
informed consent was obtained from each patient. The protocol
was registered: clinicaltrial.gov identifier no. NCT00534664.
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Figure 1 Delivery of HCC-specific modulation frequencies. (A) The generator of AM EMFs is a battery-driven RF EMF generator connected to a spoon-
shaped mouthpiece. (B) Schematic description of AM EMFs. The carrier frequency (27.12MHz) is sinusoidally modulated at specific frequencies. (C) Patient
receiving treatment with RF AM EMF. (D) HCC treatment programme consisting of sequential emission of 194 modulation frequencies for 60min.
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sAdministration of AM EMFs
The generator of AM EMFs consists of a battery-driven radio-
frequency (RF) EMF generator connected to a 1.5m long 50O
coaxial cable, to the other end of which a stainless-steel spoon-
shaped mouthpiece is connected via an impedance transformer
(Figure 1A). The RF source of the device corresponds to a class C
amplifier operating at 27.12MHz. The carrier frequency is AM
(Figure 1B) with a modulation depth of 85±5%, whereas the
modulation frequency is generated by a digital direct synthesiser
with a resolution of 10
 7. The treatment sequence is controlled by
a microcontroller (Atmel AT89S8252, Fribourg, Switzerland), that
is, duration of session, sequence of modulation frequencies and
duration of each sequence can be programmed via PC over a
RS232 interface. The RF output is adjusted to 100mW into a 50O
load, which results in an emitting power identical to that of the
device used for the treatment of insomnia (Pasche et al, 1990; Reite
et al, 1994; Pasche et al, 1996). The United States Food and Drug
Administration has determined that such a device is not a
significant risk device and it has been used in several studies
conducted in the United States (Reite et al, 1994; Pasche et al, 1996;
Kelly et al, 1997). A long-term follow-up survey of 807 patients
who have received this therapy in the United States, Europe and
Asia showed that the rate of adverse reactions was low and was not
associated with increases in the incidence of malignancy or
coronary heart disease (Amato and Pasche, 1993). The maximum
specific absorption rate (SAR) of the applied RF averaged over any
10g of tissue has been estimated to be less than 2Wkg
 1, and the
maximum temperature increase is significantly lower than 11C
anywhere in the body owing to RF absorption. The induced RF
field values within the primary and metastatic tumours are
significantly lower. In contrast, the RF fields induced during RF
ablation of tumours cause hyperthermia and result in SAR in the
range of 2.4 10
5Wkg
 1 (Chang, 2003), that is, more than 100000
times higher than those delivered by the device used in this study.
We have previously reported the discovery of HCC-specific
modulation frequencies in 46 patients with HCC using a patient-
based biofeedback approach and shown the feasibility of using AM
EMFs for the treatment of patients with cancer (Barbault et al,
2009). The treatment programme used in this study consisted of
three-daily outpatient treatments of 1h duration, which contained
HCC-specific modulation frequencies ranging between 100Hz and
21kHz administered sequentially, each for 3s (Figure 1C and
Supplementary Table S1).
The treatment method consists of the administration of AM
EMFs by means of an electrically conducting mouthpiece, which is
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Figure 2 CONSORT diagram.
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sin direct contact with the oral mucosa (Figure 1D). The patients
were instructed on the use of the device and received the first
treatment at the medical centre’s outpatient clinic. A device was
provided to each patient for the duration of the study. The patients
were advised to self-administer treatment three times a day.
Treatment was administered until tumour progression was
objectively documented. At that time, treatment was discontinued.
Treatment compliance was assessed at every return visit by
recording the number of treatments delivered in the preceding
2 months.
Efficacy end points and disease assessment
The primary end point of this trial was the proportion of patients
progression-free at 6 months. Secondary end points were
progression-free survival (PFS) (first day of treatment until
progression of disease or death) and overall survival (OS) (first
day of receiving treatment to death). Objective response was
assessed using the Response Evaluation Criteria in Solid Tumours
group classification for patients with disease assessed by either
helical multiphasic CT (Therasse et al, 2000). Whenever contrast-
enhanced US radiological assessment was used, it was performed
and reviewed by the same radiologist specialised in HCC (MCC) as
this imaging modality is investigator dependent. Tumour mea-
surements were performed at baseline and every 8 weeks. Only
patients with at least one repeat tumour measurement during
therapy were considered for response analysis. Throughout the
study, lesions measured at baseline were evaluated using the same
technique (CT or contrast-enhanced US). Overall tumour response
was scored as a complete response (CR), partial response (PR), or
stable disease (SD) if the response was confirmed at least 4 weeks
later. Alpha-fetoprotein (AFP) levels were measured every 8 weeks
in all patients throughout the study, but changes in AFP were not
an end point for assessment of response. Pain was assessed
according to the NCI-CTCAE v.3.0 (http://ctep.cancer.gov/proto-
colDevelopment/electronic_applications/docs/ctcaev3.pdf).
Statistical analyses and efficacy assessment
All eligible patients who began treatment were considered
assessable for the primary and secondary end points. A Simon
two-stage phase II minimax design was used (Simon, 1989) to
evaluate the rate of progression-free survival at 6 months. The
interim analysis was performed once enrolment into the first stage
was completed. In the first stage, 23 patients were observed. If two
or fewer patients had progression-free survival X6 months, the
trial would be terminated early for lack of efficacy. If the
progression-free survival of 3 or more of the first 23 patients
was equal or greater than 6 months, then an additional 18 patients
would be enrolled to a maximum of 41 patients. If eight or more of
the 41 had PFS of at least 6 months, we would conclude that the
treatment was efficacious. This design had a Type I error rate of
5% and a Type II error rate of 10% for the null hypothesis of a
6-month PFS rate of 10% vs the alternative of 27.5%. Kaplan–
Meier estimates of survival, PFS, and duration of response were
calculated with standard errors based on Greenwood’s formula.
These calculations were performed using the Proc Lifetest in SAS
9.2 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Patient recruitment and follow-up
From October 2005 to July 2007, 267 patients were assessed for
eligibility (Figure 2). In all, 43 patients with advanced HCC and
Child–Pugh A or B were enrolled in this study. The date of last
patient follow-up is 9 June 2011. Of these, 20 patients (46.5%) had
histological confirmation of HCC; 23 patients (53.5%) were
Table 1 Treatments received by patients with advanced HCC before
enrolment (n¼41)
No previous treatment 7
Chemoembolisation 25
131I-Lipiodol 1
Octreotide 1
Percutaneous alcohol injection therapy 1
Surgery 9
Systemic chemotherapy or sorafenib 5
Abbreviation: HCC¼hepatocellular carcinoma. Two patients had surgery and
chemoembolisation, two patients had surgery and systemic chemotherapy, one
patient had surgery and chemoembolisation and systemic chemotherapy, one patient
had surgery and percutaneous alcohol injection, one patient had surgery and
sorafenib, one patient had chemoembolisation and systemic chemotherapy and one
patient had surgery and octreotide.
Table 2 Patients’ baseline characteristics
No. %
Age (years)
Median age 64
Range 18–85
X65 19 46.3
o65 22 53.6
Sex
Female 6 14.6
Male 35 85.4
ECOG performance status
0 5 12.2
1 28 68.3
2 8 19.5
Child–Pugh status
A5 15 36.6
A6 2 4.9
B7 6 14.6
B8 5 12.2
B9 11 26.8
No cirrhosis 2 4.9
BCLC status
B 6 14.6
C 35 85.4
AFP4ULN
Yes 28 68.3
No 13 16.7
Aetiology
ETOH 2 4.9
Hepatitis B 6 14.6
Hepatitis B+C 1 2.4
Hepatitis C 22 53.7
ETOH+hepatitis C 1 2.4
NOS 9 22.0
Portal thrombosis 10 24.3
Extrahepatic disease
Yes 16 39.0
Location
Lung 6 14.6
Bone 3 7.3
Lymph nodes 4 9.8
Peritoneal carcinomatosis 1 2.4
Adrenal gland 1 2.4
Abbreviations: AFP¼a-fetoprotein; BCLC¼Barcelona Clinic Liver Cancer;
ECOG¼Eastern Cooperative Oncology Group; ETOH, ethyl alcohol; ULN, upper
limit of normal.
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sdiagnosed based on elevated levels of a-fetoprotein and character-
istic imaging findings such as vascular invasion and characteristic
differences in tumour blood flow. One patient was excluded
because liver biopsy established the diagnosis of metastatic breast
cancer. Another patient was excluded because of severely impaired
liver function (Child–Pugh C11). These two patients who did not
meet the inclusion criteria were registered as screening failures.
Hence, a total of 41 patients were eligible to receive experimental
therapy (Figure 2).
Two patients were lost to follow-up as they did not come back for
their scheduled appointments. Repeated efforts were made to reach
the patients and their families. The date of death of only one patient
is known, and no information on response to treatment is available
for either patient. Four patients withdrew consent while receiving
therapy after 8.0, 9.3, 20.3, and 21.0 months, respectively (Figure 2).
One patient elected to receive chemotherapy, one patient had poor
treatment compliance as defined by administration of less than 50%
of planned treatments at two consecutive return visits, one patient
elected to enrol in another experimental protocol, and one patient
requested to be considered for liver transplantation as part of an
extended indication, which does not fulfil the Milan criteria
(Mazzaferro et al, 1996). This latter patient experienced disease
progression and was ultimately not eligible for liver transplantation.
Of the 35 patients who discontinued experimental therapy, four died
of gastrointestinal bleeding, three of sepsis, three of hepatic failure,
one of chronic obstructive pulmonary disease, two of chemotherapy-
and chemoembolisation-related complications, and one of myocar-
dial infarction (Figure 2). The remaining 24 patients discontinued
because of disease progression assessed by imaging or significant
clinical deterioration as assessed by the investigator (Figure 2).
Estimated 60-day mortality was 27.8%; seven of 10 deaths were
directly related to progression of disease. They were caused by liver
failure in association with significant hepatic tumour involvement,
without other cause of death, other than tumour involvement. Two
deaths were secondary to gastrointestinal bleeding. One death was
due to liver failure.
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Figure 3 Progression-free and overall survival. (A) Median progression-free survival was 4.4 months (95% CI 2.1–5.3). (B) Median overall survival was 6.7
months (95% CI 3.0–10.2). (C) Long-term partial response in a patient with biopsy-proven hepatocellular carcinoma. A 76-year-old woman with hepatitis C
and Child–Pugh A5, BCLC C, biopsy-proven hepatocellular carcinoma with bilateral pulmonary metastases, who had evidence of disease progression
(þ36% by Response Evaluation Criteria in Solid Tumours (RECIST) criteria) between 3 May 2006 (first column) and 26 July 2006 (second column) while
enrolled in the SHARP study (Llovet et al, 2008b). Treatment with AM EMFs was initiated on 9 August 2006. Subsequent restaging multiphasic contrast-
enhanced computed tomographies (CTs) with images from corresponding levels (across rows) are demonstrated in the third and fourth columns over the
course of 57 months. Note that the hypervascularity of the focal hepatic lesions (arrows in first two rows) became relatively hypoenhancing on arterial phase
(20 August 2008). The patient developed main portal vein thrombosis with cavernous transformation as a complication of her cirrhosis. However, the
intrahepatic lesion size is stable regardless of enhancement pattern. Note also that the left lung base lesion resolved (4th row), and the right lung base lesion
remained stable (3rd row) over the duration of treatment. (D) Alpha-fetoprotein response in a 67-year-old patient with Child–Pugh A5, BCLC C HCC and
hepatitis C (hepatitis B negative).
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sA total of 31 patients (75.6%) had radiological evidence of
disease progression at the time of enrolment as defined by
comparison of baseline imaging studies, with imaging studies
obtained within the previous 6 months; 34 (82.9%) patients had
received therapy before enrolment, five (14.6%) of them systemic
chemotherapy or sorafenib (Table 1). Seven (17.1%) patients had
not received therapy before enrolment for the following reasons:
(1) severely impaired liver function in five cases; and (2) two
patients refused to receive chemotherapy for metastatic disease. As
shown in Table 2, the majority of patients had severely impaired
liver function as demonstrated by the fact that 22 (53.7%) patients
had Child–Pugh B disease and 35 (85.4%) BLCL stage C disease.
Treatment efficacy
Six of the first 23 patients (26.1%) had progression-free survival
X6 months, which led us to continue enrolling patients up to the
preplanned total of 41 patients (Figure 2). In total, 14 patients
(34.1%) had SD for more than 6 months, which met our
preplanned primary efficacy end point. Median progression-free
survival was 4.4 months (95% CI 2.1–5.3) and median OS was 6.7
months (95% CI 3.0–10.2) (Figure 3A and B). One patient,
previously enrolled in the SHARP study (Llovet et al, 2008b) and
with evidence of disease progression at the time of enrolment,
remains on therapy with a near complete response for 58 months
(Figure 3C). Estimated survival at 12, 24 and 36 months is
27.9% (s.e.¼7.1%), 15.2% (s.e.¼5.7%), and 10.1% (s.e.¼4.8%),
respectively. Subset analyses by Child-Pugh stage and accompany-
ing figures are reported in Supplementary Information.
A total of 28 patients were evaluable for tumour response
(Figure 2). Four (9.8%) patients had a partial response assessed
with CT with or without contrast-enhanced ultrasound (Table 3).
All partial responses were independently reviewed by two authors
(MSR and DM). Three patients had biopsy-confirmed HCC and
three had radiological evidence of disease progression at the time
of enrolment (Table 4). Two patients had Child–Pugh A, one
Child–Pugh B disease, and one had no cirrhosis. One of these
Table 3 Independently reviewed best response (N¼41)
Best response No. %
Partial response
a 4 9.8
Stable disease
b 16 39.0
Progressive disease 8 19.5
Not available for response assessment 13 31.7
aDuration of the partial responses were +58.0, 46.9, 14.5 and 5.3 months (patient
withdrew consent to undergo liver transplant).
bTo be classified as a stable disease,
patients needed to have stable disease for X12 weeks.
Table 5 Changes in AFP levels
Patient age
and gender
AFP 6 months
(ngml
 1)
Baseline AFP
(ngml
 1)
8-week AFP
(ngml
 1)
AFP variation
(%)
Treatment duration
(months)
End treatment
status
Virus
status
65 M 4.31 9.76 5.95  39.0 3.0 Progression-death HepC
67 F 888.3 9022.0 238.0  97.3 11.7 GI bleed-death HepC
64 M 4.7 4.5 2.6  42.2 8.8 AMI-death HepB
18 M 6.7 35.7 16.4  55.7 7.8 Revoked consent-death NOS
Abbreviations: AFP¼a-fetoprotein; AFP 6 months¼AFP measured within 6 months before enrolment; AMI¼acute myocardial infarction; baseline AFP¼AFP at treatment
initiation; GI¼gastrointestinal; HepB¼hepatitis B virus; HepC¼hepatitis C virus; NOS¼not otherwise specified; 8-week AFP¼AFP at 8 weeks during treatment.
Table 4 Characteristics of patients with either PR and/or long-term survival in excess of 24 months
Age at
enrolment
and sex Race
Cause/
cirrhosis
(Child–
Pugh)
Previous
treatment/
resection
AFPm/
pathology
confirmation
Extra hepatic
metastasis/
portal
thrombosis BCLC Okuda CLIP MELD
Progression
before study
entry/
response
Treatment
duration/
overall
survival
(months)
Cause
of
death
Treatment
received after
completion of
experimental
therapy
62 M Caucasian Hep
C/yes
(A5)
Yes/no Yes/yes No/no B 1 0 6 Yes/N/A 2.0/32.0 Tumour
progressed
Systemic
chemotherapy
67 F Caucasian Hep
C/yes
(B9)
Yes/no Yes/yes No/no C 2 2 11 Yes/PR 11.7/11.7 GI bleed None
30 M Black NOS/no Yes/es No/yes No/no B N/A N/A N/A No/PR 13.5/37.6 Tumour
progressed
Chemoembolisation
and systemic
chemotherapy
61 M Caucasian Hep
C/yes
(A5)
Yes/no No/no No/no C 1 1 6 Yes/SD 26.8/26.8 COPD None
56 M Caucasian Hep
B/C/yes
(A5)
No/no Yes/no No/no B 1 0 10 Yes/SD 4.9/50.3 Tumour
progressed
Chemoembolisation
63 M Caucasian Hep
C/yes
(A5)
Yes/no Yes/no No/no C 1 1 4 Yes/PR 4.9/14.3 Tumour
progressed
None
76 F Caucasian Hep
C/yes
(A5)
No/no No/no No/yes C 1 1 6 Yes/SD 44.6/44.6 Tumour
progressed
None
76 F Caucasian Hep
C/yes
(A5)
No/yes No/yes Yes/yes C 1 1 6 Yes/PR +58.0/+58.0 On therapy Still receiving
experimental
treatment
Abbreviations: AFP¼a-fetoprotein; BCLC¼Barcelona Clinic Liver Cancer; CLIP¼Cancer Liver Italian Programme; GI¼gastrointestinal; MELD¼Model for end-stage liver
disease; N/A¼not applicable; PR¼partial response; SD¼stable disease.
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spatients without biopsy-proven disease subsequently withdrew
consent after 4.9 months to undergo liver transplantation. The
patient died of progression of disease 9.4 months later before
undergoing liver transplantation. One patient with Child–Pugh B
disease had a partial response lasting 11.7 months and died of
gastrointestinal bleeding. One patient died of disease progression at
44.6 months. Overall, there were six long-term survivors with an OS
greater than 24 months and four long-term survivors with an OS
greater than 3 years. Importantly, five of the six (83%)
long-term survivors had radiological evidence of disease progres-
sion at the time of study enrolment (Table 4). Two of three
patients with the longest survival (44.6 and þ58 months) had
radiological evidence of disease progression at the time of
enrolment, BLCL stage C disease, as well as portal vein thrombosis,
three predictors of short survival (Llovet et al, 2003). Serial AFP
measurements, which predict radiological response and survival in
patients with HCC (Chan et al, 2009; Riaz et al, 2009), were available
for 23 patients. AFP decreased by 20% or more in four (9.8%)
patients following initiation of therapy (Table 5). Figure 3D shows
the time course of a 37-fold decrease in AFP in a patient who had a
long-lasting (11.7 months) partial response as assessed by CT.
In all, 11 patients reported pain before treatment initiation, 3
patients reported grade 3, 5 patients reported grade 2, and 3
patients grade 1. Five patients reported complete disappearance of
pain and two patients reported decreased pain shortly after
treatment initiation. Two patients reported no changes and two
patients reported increased pain. There were no treatment-related
grade 2, 3, or 4 toxicities. The only treatment-related adverse
events were grade 1 mucositis (one patient) and grade 1
somnolence (one patient) over a total of 266.8 treatment months.
DISCUSSION
Treatment with AM EMFs did not show any significant toxicity
despite long-term treatment. The lack of toxicity experienced by
the 41 patients presented in this report as well as the 28 patients
from our previous report (Barbault et al, 2009) can be readily
explained by the very low and safe levels of induced RF EMFs,
which are more than 100000 times lower than those delivered
during RF ablation procedures (Chang, 2003). Hence, the putative
mechanism of action of this novel therapeutic approach does not
depend on temperature changes within the tumour.
These data are comparable to recent phase II studies evaluating
the effectiveness of standard chemotherapy as well as novel
targeted therapies in HCC (Abou-Alfa et al, 2006; Boige et al, 2007;
Chuah et al, 2007; Cohn et al, 2008; Dollinger et al, 2008; Siegel
et al, 2008). In a large phase II study assessing the effects of
sorafenib in patients with HCC and Child–Pugh A and B who had
not received previous systemic treatment, Abou-Alfa et al (2006)
observed partial responses using the WHO criteria in 2.2% of
patients. Investigator-assessed median time to progression was 4.2
months, and median OS was 9.2 months. Of note, all 137 patients
from that study had evidence of disease progression after 14.8
months (Abou-Alfa et al, 2006), whereas, at the same time point,
four (9.8%) of the patients enrolled in this study did not have
evidence of disease progression. These findings suggest that RF
AM EMF may increase the time to radiological progression in
advanced HCC.
The majority of patients enrolled in this study had either failed
standard treatment options or had severely impaired liver function
that limited their ability to tolerate any form of systemic or
intrahepatic therapy. Indeed, 16 patients (39.0%) had Child–Pugh
B8 or B9 disease. Among these patients, the median progression-
free survival was 4.4 months (95% CI 1.6–7.6 months), which is
identical to that of the entire group. Five of these 16 patients
(31.3%) received therapy for more than 7.5 months, which
indicates that this therapy is well tolerated even in patients with
severely impaired liver function.
Previous treatment with standard chemotherapy or sorafenib
does not seem to impact the effectiveness of AM EMFs in the
treatment of HCC. Indeed, three of the four patients who had a
16.7.2006 10.7.2008 19.2.2009
8.7.2010 16.12.2010 19.5.2011
Figure 4 A 70-year-old man with recurrent thyroid cancer metastatic to the lungs: stable disease at 57.5 months. Long-term stable disease in a 70-year-
old man with recurrent biopsy-proven thyroid carcinoma metastatic to the lungs enrolled in the previously published feasibility study (Barbault et al, 2009).
Treatment with AM EMFs was initiated on 20 August 2006. As of 9 June 2011, the patient is asymptomatic and still receiving treatment with no evidence of
disease progression. Images through the target metastatic lesion in the right hilum demonstrate minimal size change over the 4 years, given differences in
computed tomography acquisition techniques over that time interval.
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spartial response while receiving AM EMFs had received previous
systemic therapies (chemotherapy and sorafenib) and one had
received intrahepatic therapy with
131I-lipiodol.
Tumour shrinkage as assessed by radiological imaging as well as
changes in AFP levels were documented in patients with advanced
HCC receiving RF EMF modulated at HCC-specific frequencies
administered by an intrabuccal probe. Antitumour activity in
patients with advanced HCC was exemplified by partial responses
observed in four patients (9.8%) and decreases in AFP levels
greater than 20% in four patients. A total of 18 patients (43.9%)
either had objective response or SD X6 months.
Importantly, this therapeutic approach has long-lasting
therapeutic effects in several patients with metastatic cancer.
Two of these patients, one with recurrent thyroid cancer metastatic
to the lungs (Figure 4) enrolled in our feasibility study (Barbault
et al, 2009) and the patient shown in Figure 3C, are still receiving
treatment without any evidence of disease progression and without
side effects almost 5 years after being enrolled in these studies.
These findings suggest that, in some patients, this therapeutic
approach may achieve permanent control of advanced cancer with
virtually no toxicity.
Our phase I/II study has several limitations. First, only 19 of the
41 patients had biopsy-proven HCC, and the others were
diagnosed by clinical criteria, an approach similar to that used
in a recently reported phase II trial evaluating the clinical and
biological effects of bevacizumab in unresectable HCC (Siegel et al,
2008). Importantly, analysis restricted to these 19 patients shows
rates of progression-free survival at 6 months, median progres-
sion-free survival and OS that are similar to those without biopsy-
proven HCC (Supplementary Figures 1C and D). Furthermore,
three of the four partial responses were observed in patients
with biopsy-proven HCC. Hence, these findings strongly suggest
that treatment with AM EMFs yields similar results in patients with
and without biopsy-confirmed HCC. Another potential limitation
of our study consists in the use of contrast-enhanced ultrasound
for the monitoring of some patients with HCC. It should be
pointed out that recent studies indicate that the use of this imaging
technique is comparable to that of CT scan with respect to the
measurement of HCC tumours (Choi, 2007; Maruyama et al, 2008).
Antitumour response is considered the primary end point for
phase II studies to proceed to further investigations. Studies
applying Cox proportional hazards analysis indicate that this end
point is consistently associated with survival in trials of
locoregional therapies for HCC (Llovet et al, 2002) and a recent
consensus article suggests that randomised studies are necessary to
capture the true efficacy of novel therapies in HCC (Llovet et al,
2008a). In summary, the encouraging findings from this study
warrant a randomised study to determine the impact of AM EMFs
on OS and time to symptomatic progression.
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